EXG-102031 is under clinical development by Exegenesis Bio and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how EXG-102031’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EXG-102031 overview
EXG-102031 is under development for the treatment of neovascular age-related macular degeneration. It acts by targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG2). It is administered by subretinal route. The drug candidate is being developed based on AAVarta (AAV capsid in silico evolution discovery platform) and Constellation platforms (AI assisted DNA expression cassette design).
Exegenesis Bio overview
Exegenesis Bio discovers and develops genetic medicines for eye, central nervous system (CNS) and liver-directed diseases. The company is investigating drugs for the treatment of spinal muscular atrophy, Parkinson’s disease, age related macular degeneration, Bietti’s crystalline dystrophy, hemophilia A, and phenylketonuria. It utilizes AAVarta AAV capsid in silico evolution discovery, Constellation AI-aided DNA expression cassette design, Progress data-driven protein engineering, and a commercial-scale manufacturing platform to develop its therapies. Exegenesis Bio is seeking collaborations in the areas of clinical-stage licensing opportunities, and platform technologies to improve gene delivery and manufacturing. The company operates with additional offices in the US, China, and Singapore. Exegenesis Bio is headquartered in Lower Gwynedd, Pennsylvania, the US.
For a complete picture of EXG-102031’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
